AbbVie Reports Third-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abbvie (ABBV) PT Lowered to $71 at BMO Capital
November 5, 2018 8:47 AM ESTBMO Capital analyst Alex Arfaei lowered the price target on Abbvie (NYSE: ABBV) to $71.00 (from $78.00) while maintaining a Underperform rating.
The analyst commented, "3Q18 was fine, but not great; particularly the Imbruvica beat. The market is ignoring management's long-term guidance, and signals of... More
AbbVie (ABBV) Tops Q3 EPS by 12c, Lifts FY EPS Guidance
November 2, 2018 7:48 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $2.14, $0.12 better than the analyst estimate of $2.02. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $8.22 billion.
GUIDANCE:
AbbVie sees Q4 2018 EPS of $7.90-$7.92, versus the consensus of $7.88.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More